OR WAIT null SECS
KMR Group recently assessed the duration of oncology trials and found a steady rise
KMR Group recently assessed the duration of oncology trials and found a steady rise in late stage oncology cycle times in the last 10 years. KMR Group assessed cycle time trends for more than 4,100 oncology trials using proprietary industry data across 32 companies and found that Phase II oncology trials require about one additional year, compared to trials conducted a decade ago. Phase III trials are taking almost five years, which is one and a half years longer than trials in 2003-2005. KMR defines study duration as the interval from protocol approval to database Lock.
Read the full release here.